2JOHNSON LB, KAUFFMAN CA. Voriconazole: a new triazole antifungal agent [J]. Clin Infect Dis, 2003, 36 (5): 630-637.
3SCOTF LJ, SIMPSON D. Voriconazole : a review of its use in the management of invasive fungal infections [J]. Drugs, 2007, 7 (2) : 269-298.
4HYLAND R, JONES BC, SMITH DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole [J]. Drug Metab Dispos, 2003, 31 (5) : 540-547.
5XIE W, UPPAL H, SAINI SP, et al. Orphan nuclear receptormediated xenobiotic regulation in drug metabolism [J]. Drug Discov Today, 2004, 9 (10) : 442-449.
6FINCH CK, CHRISMAN CR, BACIEWICZ AM, et al. Rifampin and rifabutin drug interactions: an update [J]. Arch Intern Med, 2002, 162(9) : 985-992.
7TANG C, LIN JH, LU AY. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? [J]. Drug Metab Dispos, 2005, 33 (5): 603 -613.
8PURKINS L, WOOD N, GHAHRAMANI P, et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration [J]. Br J Clin Pharmacol, 2003, 56 Suppl 1: 37-44.
9DONNELLY JP, de PAUW BE. Voriconazole : a new therapeuticagent with an extended spectrum of antifungal activity [J]. Clin Microbiol Infect, 2004, 10 Suppl 1 : 107-117.
10LIU P, FOSTER G, LABADIE RR, et al. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects [J]. Clin Pharmacal, 2008, 48 (1) : 73- 84.
